Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, and partner Bayer Healthcare, of Leverkusen, Germany, reported results from the phase IIIb X-VeRT trial at the European Society of Cardiology meeting in Barcelona, Spain, showing that once-daily Xarelto (rivaroxaban) may be an alternative to vitamin K antagonists in treating and reducing the risk of blood clots in nonvalvular atrial fibrillation patients undergoing elective cardioversion.